Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Sera Prognostics, Inc. (NASDAQ: SERA), a Salt Lake City–based health diagnostics company focused on precision pregnancy care and preterm birth risk prediction. As a public company, Sera files annual, quarterly, and current reports that describe its financial condition, operations, and key clinical and commercial developments.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of Sera’s business, including its focus on the PreTRM® Test, a blood-based biomarker test for individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies. These filings typically include information on revenues, operating expenses, research and development activities, and risk factors relevant to the company’s diagnostics business.
Current reports on Form 8-K document material events such as the release of quarterly financial results and significant clinical milestones. Recent 8-K filings reference press releases announcing second and third quarter financial results and the acceptance of the PRIME study for publication in a peer-reviewed journal. These filings help readers track how clinical evidence, such as the PRIME randomized controlled trial, connects to Sera’s commercial and strategic plans.
Users can also monitor Form 4 and other insider transaction filings, when available, to see reported trades by directors, officers, or significant shareholders. Stock Titan’s tools surface new SERA filings as they appear in the SEC’s EDGAR system and provide AI-powered summaries to explain key points, highlight important sections in lengthy documents, and make it easier to understand how disclosures about the PreTRM Test, payer engagement, and financial performance may relate to the company’s overall trajectory.
Sera Prognostics (SERA) disclosed an insider transaction by its Chief Financial Officer. On 11/10/2025, the officer sold 6,351 shares of Class A common stock at a weighted average price of $2.62 to cover tax withholding tied to RSU vesting, as required by the issuer’s sell-to-cover policy. The block trade occurred across multiple transactions priced between $2.30 and $3.04. After the sale, the officer beneficially owns 278,319 shares, held directly.
Sera Prognostics (SERA) filed a Form 4 reporting a routine sell-to-cover. On 11/05/2025, a director sold 221 shares of Class A common stock at a $3.04 weighted average price to satisfy tax withholding from vested RSUs. The filing notes the sale was mandated by the issuer’s “sell to cover” election and was not a discretionary trade by the insider. Following the transaction, the reporting person beneficially owns 58,032 shares, held directly. The shares were sold in multiple trades between $3.03 and $3.05.
Sera Prognostics (SERA) reported a Form 4 for its Chief Information Officer, who sold 2,000 shares of Class A common stock on 11/04/2025 at a weighted average price of $3.07.
The sale was effected under a Rule 10b5-1 trading plan adopted on May 21, 2025, with trade prices ranging from $3.02 to $3.15. Following the transaction, the officer beneficially owns 95,932 shares, held directly.
Sera Prognostics (SERA) filed a Form 4 reporting equity awards to its Chief Medical Officer. On 10/15/2025, the officer acquired 75,000 shares of Class A Common Stock represented by RSUs at a price of $0, bringing beneficial ownership of these shares to 75,000, held directly.
The filing also reports a stock option grant for 107,000 shares at an exercise price of $3.13, expiring on 10/15/2035, with 107,000 derivative securities beneficially owned directly. The RSUs vest over four years: 25% on the first anniversary of the vesting commencement date, which is October 10, 2025, then 1/12 of the remainder in quarterly installments for three years thereafter. The options vest over four years: 25% on the first anniversary of the vesting commencement date, which is October 10, 2025, then 1/36 of the remainder in monthly installments for three years thereafter.
Sera Prognostics (SERA)no securities beneficially owned as of the event date 10/01/2025. The filing was submitted as an individual report and includes an Exhibit 24.1 Power of Attorney authorizing the attorney-in-fact to sign on the reporting person’s behalf. This is a routine ownership disclosure required at the start of insider reporting.
Harrison Robert Gardner, Chief Information Officer of SERA Prognostics, Inc. (SERA), reported a planned sale of 2,000 shares of Class A common stock executed on
Sera Prognostics, Inc. insider Robert Gardner Harrison filed a Notice of Proposed Sale under Rule 144 reporting the planned sale of 2,000 common shares through Morgan Stanley Smith Barney LLC on
Director sale to cover RSU taxes: A director, Mirza Mansoor Raza, reported on
Sera Prognostics (SERA) filed a Form 144 reporting a proposed sale of 227 Class A common shares that vested as restricted stock units on
The filer states the 227 shares arose from RSU vesting on
Sera Prognostics director Sandra Lawrence reported an amended Form 4 showing the sale of 1,560 shares of Class A common stock at a weighted average price of $3.05, leaving her with 21,153 shares beneficially owned. The sales were executed under a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2025, and the Form 4 amendment corrects an administrative error in the originally reported share count. The filer states the reported price is a weighted average for multiple transactions ranging from $2.99 to $3.12 and offers to provide a breakdown on request.